ArticleJournal of asthma and allergy2026
Clinical and Cost-Effectiveness of Omalizumab in Concomitant Asthma and Chronic Rhinosinusitis with Nasal Polyps: A Real-World Exploratory Study.
Article in Journal of asthma and allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) frequently coexist, representing the severe "United Airway Disease" (UAD) phenotype. Although omalizumab is approved for both conditions individually, real-world evaluations of its clinical and economic viability for this concomitant phenotype remain limited. We evaluated the cost-effectiveness of omalizumab add-on therapy in Chinese adults with UAD. Methods: This 52-week exploratory study compared omalizumab add-on therapy (n=23) with standard care (n=17) in patients with concomitant asthma and CRSwNP. Clinical outcomes included acute exacerbations (AEs), endoscopic sinus surgery (ESS) requirements, asthma control test (ACT) scores, sinus CT Lund-Mackay (LM) scores, corticosteroid and antibiotic exposure. Cost-effectiveness was analyzed from a healthcare provider perspective using 2024 constant prices, with decision uncertainty assessed via 1000-iteration bootstrapping. Scenario analyses evaluated the economic impact of recently approved domestic biosimilars. Results: At week 52, compared with standard care, the omalizumab add-on group achieved significant reductions in annual AEs (median 0 [IQR 1.00] vs 1.0 [IQR 2.00]; Conclusion: Omalizumab provides superior multi-domain clinical control and profound antibiotic-sparing effects. While the reference originator is not cost-effective over a 52-week horizon at its baseline price in China, stepwise price reductions through centralized procurement and the emergence of affordable biosimilars provides a highly viable economic pathway. Future optimization requires dynamic value-based pricing and targeting high-burden UAD phenotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.